Inspire Gains FDA Authorisation for Sleep Apnea Therapy

The FDA has approved Inspire Medical Systems’ Inspire V obstructive sleep apnoea (OSA) neurostimulator treatment. With a focus on a complete launch in 2025, Inspire intends to begin a soft launch of the gadget in late 2024.

A mask-free substitute for continuous positive airway pressure treatment is offered by Inspire. Patients with OSA are fitted with a device that pulses the individual’s tongue to shift it out of the way as they breathe. The goal of the pulses is to stop the airway obstructions that force OSA sufferers to wake up in order to breathe. When they feel ready to go to sleep, patients use the remote to activate the implant.

According to Tim Herbert, CEO of Inspire, the gadget is “really going to improve efficiencies.” In a May earnings call, Herbert informed investors that surgeons now have one fewer device to implant since the pressure sensor lead is integrated into the neurostimulator.